Company news

Alterity Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

April 27, 2026

Alterity Receives Positive FDA Feedback on CMC Meeting

April 26, 2026

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

April 22, 2026

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

April 17, 2026

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

April 16, 2026

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

April 15, 2026

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

March 30, 2026

Alterity Receives Positive FDA Feedback From Type C Meeting

March 29, 2026

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

March 9, 2026

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

March 4, 2026

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

March 2, 2026

Half Yearly Report and Accounts

February 25, 2026

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

January 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

January 21, 2026

Alterity Board Changes

November 20, 2025

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

November 12, 2025

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

November 10, 2025

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System

November 9, 2025

Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

November 2, 2025

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

October 31, 2025

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 9, 2025

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 8, 2025

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 2, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

September 15, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

September 14, 2025

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

September 8, 2025

Alterity Raises A$20.0 million in Strategic Placement

September 8, 2025

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

September 7, 2025

Trading Halt

September 3, 2025

Alterity Therapeutics to Present at the Biotech Showcase

September 2, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

Response to ASX Query Letters

August 4, 2025

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

July 30, 2025

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

July 29, 2025

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

July 28, 2025

Positive ATH434 Results from Open-Label Phase 2 Trial in MSA

July 28, 2025

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

July 27, 2025

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

July 24, 2025

Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE

July 24, 2025

Response to ASX Price Query

July 13, 2025

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

June 23, 2025

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025

Alterity Granted U.S. FDA Fast Track Designation for ATH434

May 4, 2025

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

April 30, 2025

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

April 29, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

April 28, 2025

Options Prospectus

April 17, 2025

← Newer news releases · Older news releases →

Decks

The 5 newest of 47 decks. Every deck is listed under its year.